Noninvasive biological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar pollinosis

Allergy and Asthma Proceedings

Volumn 33, Issue 6, 2012, Pages 459-466

  Gotoh, Minoru ^a   Okubo, Kimihiro ^a   Hashiguchi, Kazuhiro ^b,c   Wakabayashi, Ken Ichiro ^d   Kanzaki, Sho ^e   Tanaka, Nobuaki ^f,g   Fujioka, Masato ^e,h   Kawashima, Kayoko ⁱ   Suematsu, Kiyochika ^c   Sasaki, Koichi ^c   Iwasaki, Manabu ^j   Yamamotoya, Hajime ^k  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Otorhinolaryngology   (Japan)

^c Medical Corporation Shinanokai   (Japan)

^d KITASATO INSTITUTE HOSPITAL   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Tanaka ENT Clinic   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h Keiyu Hospital   (Japan)

ⁱ Otemae Hospital   (Japan)

^j SEIKEI UNIVERSITY   (Japan)

^k ONO PHARMACEUTICAL CO   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; PLACEBO; POLLEN ANTIGEN; PRANLUKAST;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; JAPANESE CEDAR; MAJOR CLINICAL STUDY; NOSE OBSTRUCTION; NOSE SECRETION; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; CHILD; CHROMONES; CROSS-OVER STUDIES; CRYPTOMERIA; DOUBLE-BLIND METHOD; HUMANS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84871678481     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3615     Document Type: Article

References (48)

1. Okubo K, Kurono Y, Fujieda S, et al. Japanese guideline for allergic rhinitis. Allergol Int 60:171-189, 2011.
2. Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 162:1391-1396, 2000.
3. Soose RJ. Role of allergy in sleep-disordered breathing. Otolaryngol Clin North Am 44:625-635, 2011.
4. Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: A consensus report. Curr Med Res Opin 20:1937-1952, 2004. (Pubitemid 40179633)
5. Burton WN, Conti DJ, Chen CY, et al. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med 43:64-71, 2001. (Pubitemid 32098845)
6. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
7. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 22:1203-1210, 2006. (Pubitemid 44000740)
8. Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114(suppl):S139-S145, 2004. (Pubitemid 39440925)
9. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 124(suppl):S43-S70, 2009.
10. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 30:244-254, 2009.
11. Figueroa DJ, Borish L, Baramki D, et al. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 33: 1380-1388, 2003. (Pubitemid 37289934)
12. Peters-Golden M, Gleason MM, and Togias A. Cysteinyl leukotrienes: Multi-functional mediators in allergic rhinitis. Clin Exp Allergy 36:689-703, 2006. (Pubitemid 43972964)
13. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 32:1007-1012, 2002. (Pubitemid 34779595)
14. Peters-Golden M, and Henderson WR Jr. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 94:609-618, 2005.
15. Shirasaki H. Cysteinyl leukotriene receptor CysLT1 as a novel therapeutic target for allergic rhinitis treatment. Expert Opin Ther Targets 12:415-423, 2008. (Pubitemid 351546368)
16. Okuda M, Tomita H, Usui N, et al. Clinical study of leukotriene antagonist; ONO-1078 in the treatment of perennial allergic rhinitis - An Early Phase II study [in Japanese]. Otolgia Fukuoka 43:614-630, 1997.
17. Okuda M, Unno T, Wada T, et al. Clinical study of leukotriene antagonist ONO-1078 (pranlukast hydrate), on perennial allergic rhinitis. A double-blind, dose finding study (late phase II study) [in Japanese]. Otologia Fukuoka 43:631-657, 1997.
18. Okuda M, Kataura A, Togawa K, et al. Clinical evaluation of leukotriene antagonist; ONO-1078 (pranlukast hydrate), on perennial allergic rhinitis: a double-blind, comparative study with epinastine hydrochloride (Phase III study) [in Japanese]. Otologia Fukuoka 44:47-72, 1998.
19. Busse WW, McGill KA, and Horwitz RJ. Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 29(suppl):110-115, 1999. (Pubitemid 29314673)
20. Gotoh M, Suzuki H, and Okubo K. Delay of onset of symptoms of Japanese cedar pollinosis by treatment with a leukotriene receptor antagonist. Allergol Int 60:483-489, 2011.
21. Bystrom J, Amin K, and Bishop-Bailey D. Analysing the eosinophil cationic protein - A clue to the function of the eosinophil granulocyte. Respir Res 12:10, 2011.
22. Wakabayashi K, Hashiguchi K, Kanzaki S, et al. Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber. Allergy Asthma Proc 33:1-8, 2012.
23. Saengpanich S, Assanasen P, deTineo M, et al. Effects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope 112:47-52, 2002. (Pubitemid 34037737)
24. Miadonna A, Milazzo N, Gibelli S, et al. Nasal response to a single antigen challenge in patients with allergic rhinitis - Inflammatory cell recruitment persists up to 48 hours. Clin Exp Allergy 29:941-949, 1999. (Pubitemid 29317805)
25. Wang H, Chavali S, Mobini R, et al. A pathway-based approach to find novel markers of local glucocorticoid treatment in intermittent allergic rhinitis. Allergy 66:132-140, 2011.
26. Kuna P, Lazarovich M, and Kaplan AP. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol 97:104-112, 1996. (Pubitemid 26045974)
27. Nishioka K, Ogawa T, Saito C, et al. Major basic protein, eosinophil cationic protein, and arylsulfatase in nasal secretions of patients with Japanese cedar pollinosis. Acta Med Okayama 49:29-33, 1995.
28. Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 310:1626-1630, 1984. (Pubitemid 14108874)
29. Terada N, Konno A, Ando H, et al. Nasal allergy and leukotriene.1. Extraction and measurement of LTC4, and LTD4 in nasal secretion induced by antigen challenge, and the effect of LTC4 and LTD4 on nasal mucosa [in Japanese]. Nihon Jibiinkoka Gakkai Kaiho 90:1196-1207, 1987.
30. Norman PS, Naclerio RM, Creticos PS, et al. Mediator release after allergic and physical nasal challenges. Int Arch Allergy Appl Immunol 77:57-63, 1985. (Pubitemid 15031423)
31. Carmen Rondón, Javier Fernández, Soledad López, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. J Allergy Clin Immunol 124:1005-1011, 2009.
32. Andersson M, Andersson P, Venge P, et al. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: Effects of topical glucocorticosteroid treatment. Allergy 44:342-348, 1989. (Pubitemid 19163708)
33. Nishioka K, Saito C, Nagano T, et al. Eosinophil cationic protein in the nasal secretions of patients with mite allergic rhinitis. Laryngoscope 103:189-192, 1993. (Pubitemid 23052652)
34. Mezawa A. Nasal response to chemical mediators in nasal allergy [in Japanese]. Nihon Jibiinkoka Gakkai Kaiho 91:1444-1450, 1988.
35. Okuda M, Watase T, Mezawa A, et al. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 60:537-540, 1988.
36. Robinson DS, Assoufi B, Durham SR, et al. Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment. Clin Exp Allergy 25:1118-1127, 1995.
37. Vatrella A, Ponticiello A, Parrella R, et al. Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma. Allergy 51:547-555, 1996 . (Pubitemid 26276130)
38. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 104:1162-1167, 1999. (Pubitemid 30004974)
39. Azevedo I, de Blic J, Vargaftig BB, et al. Increased eosinophil cationic protein levels in bronchoalveolar lavage from wheezy infants. Pediatr Allergy Immunol 12:65-72, 2001. (Pubitemid 32298580)
40. Sorva R, Metso T, Turpeinen M, et al. Eosinophil cationic protein in induced sputum as a marker of inflammation in asthmatic children. Pediatr Allergy Immunol 8:45-50, 1997. (Pubitemid 27365655)
41. Okamoto N, Ikeda M, Okuda M, et al. Increased eosinophilic cationic protein in nasal fluid in hospitalized wheezy infants with RSV infection. Allergol Int 60:467-472, 2011.
42. Bisgaard H, Grønborg H, Mygind N, et al. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: Effect of the glucocorticoid budesonide. J Allergy Clin Immunol 85:891-895, 1990. (Pubitemid 20173126)
43. Benson M, Strannegård IL, Strannegård O, et al. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1beta, TNF-alpha, or neutrophils. J Allergy Clin Immunol 106:307-312, 2000. (Pubitemid 30645005)
44. Wang D, Clement P, Smitz J, et al. Monitoring nasal allergic inflammation by measuring the concentration of eosinophil cationic protein and eosinophils in nasal secretions. Allergy 50:147-151, 1995.
45. Klimek L, Wolf H, Mewes T, et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 103:47-53, 1999. (Pubitemid 29063190)
46. Ueda T, Takeno S, Furukido K, et al. Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis. Ann Otol Rhinol Laryngol 112:955-961, 2003. (Pubitemid 37429639)
47. Endo S, Gotoh M, Okubo K, et al. Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber. In press.
48. Wang D, Clement P, De Waele M, et al. Study of nasal cytology in atopic patients after nasal allergen challenge. Rhinology 33: 78-81, 1995.